Project Grant SB1HL174247
Award Date
9/15/24
Completion Date
8/31/25
Dollars Obligated
$1M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Novomedix LLC (XQYMHKGDMU75)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92126, USA
Similar Awards
This federal Project Grant award of $680,583 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Mayo Clinic supports research focused on discovering genetic modifiers and therapies for anthracycline-induced cardiotoxicity. The key objectives are to: Confirm FABP7 and GPNMB as therapeutic target genes for anthracycline-induced cardiotoxicity, and explore the role of cardiac aging using the killifish model. Test the hypothesis that epicardial...
This Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Washington University to elucidate the mechanisms of cardiovascular toxicity associated with tyrosine kinase inhibitor (TKI) cancer treatments. The research aims to leverage patient-derived induced pluripotent stem cells to model TKI-induced vascular dysfunction and identify candidate compounds that can mitigate these adverse cardiovascular...
This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,488,899 to Young Therapeutics LLC to develop and validate two proprietary protein kinase inhibitor compounds, YT-002 and YT-004. The research aims to advance these compounds through preclinical studies, including optimizing drug formulations, conducting detailed pharmacokinetic and pharmacodynamic assessments, and performing long-term...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $297,720 to Filamentech, Inc. to develop the MUSICO platform, an in silico tool for evaluating the effects of disease and drug treatments on cardiomyopathies. The platform aims to integrate diverse experimental data to predict muscle behavior across molecular, cellular, and whole heart scales, enabling more efficient drug development...
This $697,952 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the molecular mechanisms underlying osimertinib-induced cardiac dysfunction and explore potential therapeutic targets. The key objectives are to: 1) Examine the association between the downregulation of myosin light chain kinase 3 (MYLK3) and osimertinib-induced contractile dysfunction, and assess whether overexpressing MYLK3 can prevent this...
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...
This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...